Lack of HIN-1 methylation in BRCAl-linked and "BRCA1-like" breast tumors

被引:0
|
作者
Krop, I
Maguire, P
Lahti-Domenici, J
Lodeiro, G
Richardson, A
Johannsdottir, HK
Nevanlinna, H
Borg, A
Gelman, R
Barkardottir, RB
Lindblom, A
Polyak, K
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[5] Karolinska Hosp, S-10401 Stockholm, Sweden
[6] Univ Hosp Iceland, Dept Pathol, Cell Biol Lab, Reykjavik, Iceland
[7] Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, FIN-00290 Helsinki, Finland
[8] Univ Lund Hosp, Dept Oncol, S-22185 Lund, Sweden
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We recently identified a candidate tumor suppressor gene, HIN-1, that is silenced due to methylation in the majority of sporadic breast carcinomas and is localized to 5q33-qter, an area frequently lost in BRCA1 tumors and thought to harbor a BRCA1 modifier gene. To establish whether germ-line mutations in HIN-1 may influence breast cancer risk, we sequenced the HIN-1 coding region in 10 familial breast cancer patients with positive logarithm of the odds scores of at least one of the markers flanking HIN-1. We also sequenced the HIN-1 coding region in 15 BRCA1 and 35 sporadic breast tumors to determine whether HIN-1 is the target of the frequent 5q loss in BRCA1 tumors. No sequence alterations were found in any of the cases analyzed. However, analysis of HIN-1 promoter methylation status revealed that in striking contrast to sporadic cases, there is a nearly complete lack of HIN-1 methylation in BRCA1 tumors (P < 0.0001). Sporadic breast tumors with a "BRCA1-like" histopathological phenotype also demonstrated significantly lower frequency of HIN-1 promoter methylation (P = 0.01) compared with other cancer types, and there was also a difference among tumors based on their estrogen receptor and HER2 status (P = 0.006), suggesting that HIN-1 methylation patterns are associated with specific breast cancer subtypes.
引用
收藏
页码:2024 / 2027
页数:4
相关论文
共 50 条
  • [1] Lack of HIN-1 methylation defines specific breast tumor subtypes including medullary carcinoma of the breast and BRCA1 linked tumors
    Tisserand, P
    Fouquet, C
    Barrois, M
    Gallou, C
    Dendale, R
    Stoppa-Lyonnet, D
    Sastre-Garau, X
    Fourquet, A
    Soussi, T
    [J]. CANCER BIOLOGY & THERAPY, 2003, 2 (05) : 559 - 563
  • [2] HIN-1 and the nosology of breast cancer
    Silver, DP
    [J]. CANCER BIOLOGY & THERAPY, 2003, 2 (05) : 564 - 565
  • [3] Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types
    Krop, I
    Player, A
    Tablante, A
    Taylor-Parker, M
    Lahti-Domenici, J
    Fukuoka, J
    Batra, SK
    Papadopoulos, N
    Richards, WG
    Sugarbaker, DJ
    Wright, RL
    Shim, J
    Stamey, TA
    Sellers, WR
    Loda, M
    Meyerson, M
    Hruban, R
    Jen, J
    Polyak, K
    [J]. MOLECULAR CANCER RESEARCH, 2004, 2 (09) : 489 - 494
  • [4] Promoter methylation of HIN-1 in the progression to esophageal squamous cancer
    Guo, MingZhou
    Ren, JingLi
    Brock, Malcolm V.
    Herman, James G.
    Carraway, Hetty E.
    [J]. EPIGENETICS, 2008, 3 (06) : 336 - 341
  • [5] Methylation of the DAPK, HIN-1 and FHIT genes in head and neck cancer
    Dalay, N.
    Yalniz, Z.
    Demokan, S.
    Demir, D.
    Gozeler, M.
    Suoglu, Y.
    [J]. EJC SUPPLEMENTS, 2008, 6 (09): : 150 - 150
  • [6] Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer
    Spitzwieser, Melanie
    Holzweber, Elisabeth
    Pfeiler, Georg
    Hacker, Stefan
    Cichna-Markl, Margit
    [J]. BREAST CANCER RESEARCH, 2015, 17
  • [7] Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer
    Melanie Spitzwieser
    Elisabeth Holzweber
    Georg Pfeiler
    Stefan Hacker
    Margit Cichna-Markl
    [J]. Breast Cancer Research, 17
  • [8] BRCA1-Like Triple Negative Tumors: Clinicopathological Variables and Chemosensitivity to Alkylating Agents
    Wesseling, J.
    Lips, E. H.
    Oonk, A. M. M.
    Smits, R. M.
    van Rijn, C. C. M.
    Mulder, L.
    Laddach, N.
    Savola, S. S.
    Wessels, L. F. A.
    Nederiof, P. M.
    Rodenhuis, S.
    Imholz, A. L. T.
    [J]. CANCER RESEARCH, 2011, 71
  • [9] Aberrant promoter methylation of HIN-1 gene may contribute to the pathogenesis of breast cancer: a meta-analysis
    Dai, Di
    Dong, Xi-Hua
    Cheng, Shi-Tong
    Zhu, Ge
    Guo, Xiao-Lin
    [J]. TUMOR BIOLOGY, 2014, 35 (08) : 8209 - 8216
  • [10] Aberrant methylation of HIN-1 (high in normal-1) is a frequent event in many human malignancies
    Shigematsu, H
    Suzuki, M
    Takahashi, T
    Miyajima, K
    Toyooka, S
    Shivapurkar, N
    Tomlinson, GE
    Mastrangelo, D
    Pass, HI
    Brambilla, E
    Sathyanarayana, UG
    Czerniak, B
    Fujisawa, T
    Shimizu, N
    Gazdar, AF
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (04) : 600 - 604